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Abstract
Background: Airway eosinophilia is a predictor of steroid responsiveness in steroid-naı¨ve asthma. However, the relationship
between airway eosinophilia and the expression of FK506-binding protein 51 (FKBP51), a glucocorticoid receptor co-
chaperone that plays a role in steroid insensitivity in asthma, remains unknown.
Objective: To evaluate the relationship between eosinophilic inflammation and FKBP51 expression in sputum cells in
asthma.
Methods: The FKBP51 mRNA levels in sputum cells from steroid-naı¨ve patients with asthma (n = 31) and stable asthmatic
patients on inhaled corticosteroid (ICS) (n = 28) were cross-sectionally examined using real-time PCR. Associations between
FKBP51 levels and clinical indices were analyzed.
Results: In steroid-naı¨ve patients, the FKBP51 levels were negatively correlated with eosinophil proportions in blood
(r =20.52) and sputum (r =20.57), and exhaled nitric oxide levels (r =20.42) (all p,0.05). No such associations were
observed in patients on ICS. In steroid-naı¨ve patients, improvement in forced expiratory volume in one second after ICS
initiation was correlated with baseline eosinophil proportions in blood (r = 0.74) and sputum (r = 0.76) and negatively
correlated with FKBP51 levels (r =20.73) (all p,0.0001) (n = 20). Lastly, the FKBP51 levels were the lowest in steroid-naı¨ve
asthmatic patients, followed by mild to moderate persistent asthmatic patients on ICS, and the highest in severe persistent
asthmatic patients on ICS (p,0.0001).
Conclusions: Lower FKBP51 expression in sputum cells may reflect eosinophilic inflammation and glucocorticoid
responsiveness in steroid-naı¨ve asthmatic patients.
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Introduction
Asthma is a chronic inflammatory disorder of the airways in
which eosinophils, Th2 cells, and Th2-type cytokines play a role
[1]. Glucocorticosteroid (GC), an established key treatment in
asthma, efficiently reduces cytokine production and induces
apoptosis of eosinophils [2] and Th2 cells via GC receptor a
(GRa). Thus, eosinophilia in asthma is responsive to GC; steroid-
naı¨ve asthmatic patients with blood [3,4] or sputum [3,5]
eosinophilia show greater improvement in lung function after
GC treatment than patients without eosinophilia.
FK506-binding protein 51 (FKBP51) is a co-chaperone of GR
and is expressed in various tissues and cell types [6]. FKBP51 is
induced by the auto-regulatory process of GC-activated GR [7],
modulates GRa activity, and plays a role in GC insensitivity,
which may be a homeostatic reaction for regulating the effects of
GC, similar to the reduction in GR number following GC
treatment [8]. In steroid-naı¨ve patients with asthma, lower
expression of FKBP51 mRNA in airway epithelial cells [9] and
in peripheral blood mononuclear cells [10] is correlated with
greater improvement in lung function after GC treatment,
suggesting that low expression of FKBP51 may be a mechanism
underlying the GC sensitivity. However, a potential association
between FKBP51 expression and airway inflammatory cells, in
particular eosinophils, has not been reported.
In this study, we examined FKBP51 expression in induced
sputum cells in patients with asthma to test the hypothesis that the
level of FKBP51 expression is down-regulated in eosinophilic
inflammation in steroid-naı¨ve asthma, and that this down-
regulation disappears in patients on inhaled corticosteroid (ICS)
treatment.
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Patients and Methods
Patients
Newly referred steroid-naı¨ve patients with asthma and stable
patients with asthma who were treated with ICS at the Asthma
Clinic in the Kyoto University Hospital were enrolled. Asthma was
defined according to the American Thoracic Society criteria [11].
The asthmatic patients on ICS were stable, and they had been free
of exacerbations for 4 weeks or more. Patients who had smoked
within the previous 6 months or who had failed sputum induction
were excluded. The disease severity of asthma on ICS was
classified into four categories: intermittent, mild persistent,
moderate persistent, and severe persistent, according to the
Global Initiative for Asthma guidelines, as revised in 2002 [12],
after determining the minimum medication necessary to maintain
control.
Healthy participants who had not smoked within the previous 6
months were recruited from our hospital staff.
The study protocol (UMIN000005106) was approved by the
Ethics Committee of Kyoto University, and written informed
consent was obtained from all participants.
Methods
In this study, patients with asthma cross-sectionally underwent
the following examination: fractional exhaled nitric oxide (FeNO)
levels, pulmonary function test, sputum induction, and blood test.
In steroid-naı¨ve patients with asthma, a follow-up pulmonary
function test was also performed after they were treated with the
minimum ICS dose needed to maintain control.
Peripheral blood was obtained from healthy controls, and
eosinophils were purified as described below.
Measurement of FeNO Levels
FeNO levels at an expiratory flow rate of 50 ml/s were
measured with a chemiluminescence analyzer (NOA 280; Sievers,







asthmatics on ICS p-value{
Patients, number 31 6 22
Gender, male/female 16/15 3/3 11/11 0.99{
Age, years 53617 57623 57616 0.48{
Smoking history, ex/never 7/24 1/5 10/12 0.15{
Disease duration, years 466 10612 17619 0.0008"
Atopic status`, yes/no 22/9 4/2 18/4 0.60{
Doses of ICS1, mg daily – 2836134 12146696 0.0001#
FEV1, % predicted 100626 101627 83625 0.01
{
Exhaled nitric oxide levels, ppb 35631 42620 37632 0.50{
Blood eosinophils, % 464 466 464 0.94#
Sputum eosinophils, % 11622 565 7610 0.87#
Serum IgE, IU/ml 83 (5–1106) 86 (9–220) 185 (5–1800) 0.19"
Values are given as means 6 SD or medians (range).
*included four patients with mild and two with moderate persistent asthma.
{with the x2 test or analysis of variance.
`Patients were considered atopic when they were positive for one or more serum allergen-specific IgE antibodies against house dust, Japanese cedar pollen, mixed
gramineae pollen, mixed weed pollen, mixed mold, cat dander, dog dander, and Trichophyton rubrum.
1Equivalent to fluticasone propionate.
"by Kruskal Wallis test,
#by unpaired t-test or analysis of variance after data were log-transformed.
Abbreviations: ICS, inhaled corticosteroid; FEV1; forced expiratory volume in one second.
doi:10.1371/journal.pone.0065284.t001
Figure 1. FKBP51 levels in induced sputum cells in patients with
asthma. FKBP51 mRNA levels normalized to b2 microglobulin mRNA
levels in induced sputum cells became progressively higher from
steroid-naı¨ve asthmatic patients (naı¨ve, n = 31), to mild to moderate
asthmatic patients on inhaled corticosteroid (mild to moderate, n = 6),
and then to severe persistent asthmatic patients on inhaled cortico-
steroid (severe, n = 22) (p,0.0001 by the Kruskal-Wallis test). *Signifi-
cant by the Wilcoxon rank-sum test. Values and bars represent means.
doi:10.1371/journal.pone.0065284.g001
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Boulder, Colorado, USA) [13] according to current guidelines
[14].
Pulmonary Function Test
After FeNO measurements, pre-bronchodilator forced expira-
tory volume in one second (FEV1) was measured using a Chest
Graph HI-701 spirometer (Chest, Tokyo, Japan). Spirometry was
performed according to the standards of the American Thoracic
Society and the European Respiratory Society [15]. For steroid-
naı¨ve patients with asthma, follow-up FEV1 was also measured.
Changes in FEV1 were calculated as 100 6 (FEV1 at the 2
nd
measurement 2 FEV1 at baseline)/FEV1 at baseline.
Sputum Induction, RNA Isolation from Sputum Cells,
Real-time PCR, and Immunostaining for FKBP51
Expression in Sputum Cells
Sputum induction and processing were performed as described
previously [16]. Adequate plugs of sputum were separated from
saliva, stored at 4uC, and processed within 2 hours. The sputum
plugs were treated with 0.1% dithiothreitol (Sputasol, Oxoid Ltd.,
Hampshire, UK) followed by Dulbecco’s phosphate-buffered
saline (PBS). After centrifugation, supernatants were removed,
and cell pellets were re-suspended in PBS. Sputum cells were
mounted on slides by cytocentrifugation, air-dried, and fixed in
acetone/methanol (75:25). Cell differentials were determined by
counting at least 400 non-squamous cells on a slide that was
stained with the May-Gru¨nwald-Giemsa method. The remaining
slides were stored at 220uC and used for immunostaining as
described below.
Total RNA was extracted from the remaining cells using an
RNeasy Mini kit (Qiagen, Osaka, Japan). cDNA was synthesized,
and real-time PCR was performed using the ABI Prism 7300
sequence detection system (Applied Biosystems, Tokyo, Japan)
with SYBR green (Qiagen). The relative quantity of FKBP51
mRNA expression levels was normalized to the mRNA expression
levels of b2 microglobulin (b2MG) in the same sample. The specific
primer sets used were forward 59-CCAAAGCTGTT-
GAATGCTGTGA-39 and reverse 59-CAAACTCGTTCAT-
GAGCAGCTG-39 for FKBP51, and forward 59-
TGTCTTTCAGCAAGGACTGGTC-39 and reverse 59-
CAAACCTCCATGATGCTGC-39 for b2MG [17].
We also evaluated FKBP51 protein expression with immuno-
cytochemistry in sputum cells. For double immunostaining,
previously prepared samples on the slides were first blocked with
Figure 2. Associations between FKBP51 levels and eosinophilic inflammation in steroid-naı¨ve patients with asthma. Associations
between FKBP51 mRNA levels normalized to b2 microglobulin mRNA levels and a) blood and b) sputum eosinophil proportions (n = 31 each) and c)
exhaled nitric oxide levels (n = 30) in steroid-naı¨ve patients with asthma.
doi:10.1371/journal.pone.0065284.g002
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CAS Block (Invitrogen Corp., Carlsbad, California, USA) and
then incubated with either rabbit anti-human FKBP51 (4 mg/ml)
(Santa Cruz Biotechnology, Santa Cruz, California, USA) or
rabbit IgG (Santa Cruz Biotechnology) at the same concentration,
and either mouse anti-human major basic protein (MBP;
Chemicon, Temecula, California, USA) or mouse IgG (Sigma-
Aldrich, Tokyo, Japan). After rinsing in PBS, samples were
incubated with Alexa Fluor 488 donkey anti-rabbit IgG (Invitro-
gen) and Alexa Fluor 546 goat anti-mouse IgG (Invitrogen).
Samples were viewed with a fluorescence microscope. Positive
staining was green for the FKBP51 antigen and red for the MBP
antigen.
Purification of Blood Eosinophils, Real-time PCR, and
Immunostaining for FKBP51 Expression in Purified Blood
Cells
Peripheral blood was obtained from healthy controls, and
FKBP51 mRNA expression in purified eosinophils, neutrophils
and mononuclear cells [18] was examined. Briefly, granulocytes
were isolated from mononuclear cells by sedimentation with 2%
dextran, followed by centrifugation on 1.103 and 1.085 Percoll
(GE Healthcare, Uppsala, Sweden) density gradients as modified
from previous reports [18,19]. After lysis of red blood cells with
0.2% and 1.6% saline, eosinophils and neutrophils were purified
by negative and positive selection, respectively, using anti-CD16
immunomagnetic beads and the mini-MACS system (Miltenyi
Biotec, Bergish Gladbach, Germany).
Total RNA was extracted from individual pools of purified
eosinophils, neutrophils, and mononuclear cells, and the levels of
FKBP51 mRNA expression normalized to b2MG were determined
as described above.
We also evaluated FKBP51 protein expression with immuno-
cytochemistry in individual pools of purified eosinophils, neutro-
phils, and mononuclear cells. Purified blood cells were smeared on
slides, air-dried, fixed in acetone/methanol (75:25), and immuno-
stained as described above.
RNA Quality Assessment
RNA quality was determined using the Experion Automated
Electrophoresis System (BIO-RAD, Tokyo, Japan) according to
the manufacturer’s instructions. RNA integrity was expressed as
the RNA quality indicator (RQI), which ranged from 1 (degraded)
Figure 3. Associations between pretreatment FEV1 and eosinophilic inflammation and FKBP51 levels in steroid-naı¨ve patients with
asthma. Associations between pretreatment FEV1 (% predicted) and a) blood and b) sputum eosinophil proportions and c) FKBP51 mRNA levels
normalized to b2 microglobulin mRNA levels in induced sputum cells in steroid-naı¨ve patients with asthma (n = 31). Abbreviation: FEV1, forced
expiratory volume in one second.
doi:10.1371/journal.pone.0065284.g003
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to 10 (intact) [20]. Samples were categorized as having poor RNA
integrity if 1# RQI #4, as having moderate RNA integrity if 4,
RQI #7, and as having high RNA integrity if 7, RQI #10,
according to the manufacturer’s instructions.
Statistical Analysis
JMP system version 6 (SAS Institute Japan; Tokyo, Japan) was
used. Data are expressed as the mean 6 SD or median (range).
Eosinophil proportions in blood and sputum, FKBP51 mRNA
levels normalized to b2MG in sputum cells, ICS doses, and changes
in FEV1 were log-transformed to achieve normal distributions. For
parametric data, Pearson correlation coefficients were used to
analyze the relationships among the data, and unpaired t-test was
used to compare two groups. For comparison of three groups, the
chi-squared test, Kruskal-Wallis test, or analysis of variance was




The patients’ characteristics are shown in Table 1. A total of six
patients with mild to moderate persistent asthma and 22 patients
with severe persistent asthma were included in the group of
asthmatic patients on ICS. Severe persistent asthmatics on ICS
showed the longest disease duration and the lowest FEV1 among
the three patient groups (Table 1). Sputum and blood eosinophil
proportions did not differ among the three groups. One steroid-
naı¨ve patient with asthma was unable to undergo FeNO
measurement because of time constraints. The average RQI of
our sputum samples was 8.561.9. The RQI was independent of
the cell type; no association was found between RQI and
proportion of cell type (neutrophils (r =20.06, p = 0.67), mono-
nuclear cells (r = 0.15, p = 0.29), or eosinophils (r = 0.09, p = 0.54)).
FKBP51 Expression in Induced Sputum Cells from Steroid-
naı¨ve Asthmatic Patients
The level of FKBP51 expression in induced sputum cells in
steroid-naı¨ve patients with asthma was significantly lower than that
in patients on ICS (p,0.0001) (Fig. 1). In steroid-naı¨ve patients
with asthma, FKBP51 expression was significantly inversely
correlated with eosinophil proportions in blood (r =20.52,
p = 0.003) and sputum (r =20.57, p = 0.0008) (Fig. 2a, b), and
with FeNO levels (r =20.42, p = 0.019) (Fig. 2c). The significant
correlation between FKBP51 expression and sputum eosinophil
proportions remained even after the right most and lowest outlier
in Fig. 2b was excluded from the analysis (r =20.45, p = 0.013).
When using a second order regression equation for FKBP51
Figure 4. Associations between changes in FEV1 after ICS initiation and pretreatment eosinophilic inflammation and FKBP51 levels.
Associations between changes in FEV1 after ICS initiation and pretreatment a) blood and b) sputum eosinophil proportions and c) FKBP51 mRNA
levels normalized to b2 microglobulin mRNA levels in steroid-naı¨ve patients with asthma (n = 20). Abbreviation: FEV1, forced expiratory volume in one
second; ICS, inhaled corticosteroid.
doi:10.1371/journal.pone.0065284.g004
Eosinophilic Inflammation and FKBP51 in Asthma
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expression levels and sputum eosinophil proportions in steroid-
naı¨ve patients with asthma, FKBP51 expression in a sputum non-
eosinophil cell (i.e., neutrophil, mononuclear cell, or lymphocyte)
was estimated to be 6.1 times higher than that in a sputum
eosinophil. We applied 100 to ‘‘sputum eosinophil proportion’’ in
the equation of ‘‘log10 FKBP51 (expression normalized to
b2MG) = 0.948 2 0.246 6 (log10 sputum eosinophil proportion)
2 0.101 6 (log10 sputum eosinophil proportion 2 0.246)
20 to
estimate FKBP51 expression in a sputum eosinophil, whereas 0.01
was used to estimate FKBP51 expression in a non-eosinophil cell.
FEV1 (% predicted) was significantly negatively correlated with
eosinophil proportions in blood (r =20.47, p = 0.008) (Fig. 3a) and
sputum (r =20.49, p= 0.006) (Fig. 3b), and was positively
correlated with FKBP51 expression (r = 0.60, p = 0.0004) (Fig. 3c).
The significant correlation between FKBP51 expression and FEV1
(% predicted) remained after the left most outlier in Fig. 3c was
excluded from the analysis (r = 0.44, p= 0.015). No significant
associations were seen between FKBP51 expression and sputum
neutrophil or lymphocyte proportions or other clinical indices
including sex, age, smoking history, disease duration, and atopic
status (data not shown). Epithelial cell counts were too low for
analysis (0.360.5%).
A total of 20 steroid-naı¨ve asthmatic patients were followed up
at our hospital. They underwent a 2nd pulmonary function test
11.463.8 months later when they were on minimum ICS doses to
maintain control (3996241 mg daily equivalent to fluticasone
propionate). Changes in FEV1 (24.7673.7%) from baseline to the
2nd measurement were significantly positively correlated with
baseline eosinophil proportions in blood (r = 0.74, p,0.0001)
(Fig. 4a) and sputum (r = 0.76, p,0.0001) (Fig. 4b), and were
negatively correlated with FKBP51 expression (r =20.73,
p,0.0001) (Fig. 4c). We did not observe any differences in sex,
Figure 5. Representative images of immunostaining of sputum cells from asthmatic patients. Case 1 (68-year-old male) and case 2 (72-
year-old female) were steroid-naı¨ve patients. Case 3 (79-year-old male) and case 4 (55-year-old female) were patients with severe persistent asthma
on high-dose inhaled corticosteroid. Column A: staining with anti-FKBP51 antibody, column B: merged image of staining with anti-major basic
protein antibody (MBP) and anti-FKBP51 antibody. Red indicates MBP, and green indicates FKBP51.
doi:10.1371/journal.pone.0065284.g005
Eosinophilic Inflammation and FKBP51 in Asthma
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age, baseline FEV1 (% predicted), eosinophil proportions in blood
and sputum, or FKBP51 mRNA levels between the 20 patients and
the 11 patients who were lost to follow-up.
Using immunocytochemistry, we observed that FKBP51
expression was qualitatively weaker in sputum eosinophils than
in sputum neutrophils and mononuclear cells in steroid-naı¨ve
asthmatic patients (Fig. 5, cases 1,2).
FKBP51 Expression in Induced Sputum Cells in Asthmatic
Patients on ICS
In asthmatic patients on ICS, the level of FKBP51 expression in
patients with severe persistent asthma (n= 22) was significantly
higher than that in patients with mild to moderate persistent
asthma (n = 6) (p = 0.033) (Fig. 1). ICS doses were not significantly
positively correlated with FKBP51 expression (r = 0.28, p= 0.15)
(n = 28).
In contrast to steroid-naı¨ve patients with asthma, no significant
associations were observed between FKBP51 expression and
eosinophil proportions in blood (r = 0.27, p = 0.17) and sputum
(r = 0.28, p = 0.15) or FeNO levels (r = 0.23, p= 0.23) in stable
asthmatic patients on ICS. Associations were also not observed
between FKBP51 expression and sputum neutrophil or lymphocyte
proportions, FEV1 (% predicted), or other clinical indices (data not
shown). Epithelial cell counts were too low for analysis
(0.460.7%).
In asthmatic patients on ICS, immunostaining for FKBP51 in
sputum eosinophils, particularly in the nucleus, was comparable to
or stronger than that in neutrophils and mononuclear cells in
severe persistent asthmatic patients on ICS (Fig. 5, cases 3, 4).
FKBP51 mRNA and Protein Expression in Purified Blood
Eosinophils and Non-eosinophils
Eosinophils, neutrophils, and mononuclear cells were purified
from the peripheral blood of 11 healthy controls (6 males and 5
females, 34.764.3 years old). The FKBP51 mRNA levels in
purified mononuclear cells were significantly higher than those in
purified eosinophils, but not different from those in purified
neutrophils. When neutrophils and mononuclear cells were
analyzed together as non-eosinophils, FKBP51 mRNA levels in
non-eosinophils were 6.0613.8 fold higher than those in
eosinophils (p = 0.026).
Immunostaining for FKBP51 in purified eosinophils was also
weaker than that in neutrophils or mononuclear cells (Fig. 6).
Discussion
To the best of our knowledge, this is the first study that clarifies
the associations between the level of FKBP51 mRNA expression in
induced sputum cells and clinical indices in patients with asthma,
in particular, patients with eosinophilic inflammation. We showed
Figure 6. Representative images of immunostaining of purified blood eosinophils and non-eosinophils from healthy controls. Case
1 (46-year-old female), case 2 (36-year-old female), case 3 (35-year-old male). Column A: staining with anti-FKBP51 antibody, column B: merged image
of staining with anti-major basic protein antibody (MBP) and anti-FKBP51 antibody. Red indicates MBP, and green indicates FKBP51.
doi:10.1371/journal.pone.0065284.g006
Eosinophilic Inflammation and FKBP51 in Asthma
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that the level of FKBP51 expression in induced sputum cells 1) was
significantly inversely correlated with eosinophilic inflammation
and positively correlated with improvement in FEV1 with ICS
treatment in steroid-naı¨ve patients with asthma and 2) became
progressively higher from steroid-naı¨ve asthmatic patients, to mild
to moderate persistent asthmatic patients on ICS, and then to
severe persistent asthmatic patients on ICS. No correlation of
eosinophilic inflammation to FKBP51 expression in induced
sputum cells was observed in patients on ICS.
FKBP51 is a co-chaperone of GR. It was originally discovered
as a member of the progesterone receptor complex [21] and was
then described in 1999 as playing a major role in steroid resistance
in squirrel monkeys with high circulating levels of GC [22,23]. In
previous studies using cultured squirrel monkey lymphocytes and
human lymphocytes, FKBP51 mRNA was induced by GC [24],
and its overexpression was thought to inhibit GRa signaling by
reducing the binding affinity of GC to GRa [22,25], impairing
nuclear translocation of GRa [26] and promoting nuclear
translocation of GRb [27].
In steroid-naı¨ve asthmatic patients, the level of FKBP51
expression in induced sputum cells was inversely correlated with
the proportions of blood and sputum eosinophils, suggesting that
the level of FKBP51 expression in eosinophilic inflammation was
lower than that in non-eosinophilic inflammation under steroid-
naı¨ve conditions. Lower FKBP51 expression in eosinophilic airway
inflammation may be advantageous for GC signaling via GRa and
may accelerate eosinophil apoptosis [2,28]. In an earlier report,
lower baseline FEV1 in patients with eosinophilic inflammation
was a strong predictor of GC responsiveness [4]. In our study,
eosinophilic inflammation and lower FKBP51 expression were
associated with lower baseline FEV1 (% predicted) and greater
improvement in FEV1 after ICS treatment. Collectively, lower
FKBP51 may be one of the mechanisms underlying the
relationship between eosinophilia with lower baseline FEV1 and
GC responsiveness in steroid-naı¨ve asthmatic patients.
The current findings imply that the level of FKBP51 expression
in sputum eosinophils may be lower than that in sputum
neutrophils and mononuclear cells. Indeed, immunostaining of
sputum cells revealed a weaker FKBP51 expression in eosinophils
than that in neutrophils and mononuclear cells in steroid-naı¨ve
asthmatic patients. To confirm these findings, we purified
eosinophils from neutrophils and mononuclear cells using blood
samples obtained from healthy controls because purification of
sputum eosinophils by separation from non-eosinophils was
technically difficult. Using purified blood cells, we first observed
that FKBP51 expression in eosinophils was significantly lower than
that in non-eosinophils. Moreover, the ratio of FKBP51 expression
in eosinophils to FKBP51 expression in non-eosinophils in blood
was comparable to the estimated ratio in sputum cells. Taken
altogether, the findings in blood cells may support the findings that
lower FKBP51 expression in sputum cells reflects eosinophilic
inflammation in steroid-naı¨ve patients with asthma. Nonetheless,
for the differences in FKBP51 expression levels between sputum
cells from steroid naı¨ve patients and those from patients on ICS,
which is mentioned below, we should consider the possibility that
these differences may reflect a mean change between the patient
groups studied and not simply reflect changes at the cellular level
because we did not purify sputum cell populations in this study.
In contrast to the steroid-naı¨ve group, negative associations
between FKBP51 expression and eosinophilic inflammation were
not observed in patients with asthma who were treated with ICS.
The level of FKBP51 expression in severe persistent asthmatics on
ICS was significantly higher than that in mild to moderate
persistent asthmatics on ICS and in steroid-naı¨ve patients. The
highest expression of FKBP51 in our patients with severe persistent
asthma on ICS is consistent with the findings in earlier reports that
high expression of FKBP51 in steroid-naı¨ve conditions is associated
with insensitivity to GC treatment [9,10] and reduced GC-
mediated inhibition of interleukin-13 signaling [7]. Meanwhile, the
treatment conditions in our study and in earlier studies were
different, and the high level of FKBP51 in severe persistent
asthmatic patients on ICS in our study is thought to be mostly
induced by high doses of ICS. Despite this, overexpression of
FKBP51 may be involved in the pathogenesis of severe persistent
asthmatic patients, including steroid insensitivity.
Our study has several limitations. First, we did not examine the
level of FKBP51 expression and its function in purified eosinophils
and other cells in sputum. This was because sputum eosinophil
samples (8.9617.0%) (n = 59) were contaminated with other cell
types; neutrophils (63.3622.6%), mononuclear cells
(25.8620.3%), lymphocytes (1.861.6%), and epithelial cells
(0.460.6%), and purification of sputum eosinophils by separation
from non-eosinophils was technically difficult. Instead, we
performed double immunostaining for sputum cells and examined
FKBP51 expression in blood eosinophils and neutrophils or
mononuclear cells. Second, FKBP51 expression levels in severe
persistent asthmatics in the steroid-naı¨ve condition are unknown
because reducing ICS to examine changes in FKBP51 expression
in severe persistent asthmatics is ethically difficult. A longitudinal
study with a larger sample size is needed to determine the FKBP51
expression levels in severe persistent asthmatics in the steroid-naı¨ve
condition. In addition, we need to examine the actual FKBP51
function in response to GC, including the acceleration of nuclear
translocation of GRb in sputum cells. This may be achieved by
knocking down FKBP51 expression using siRNA in sputum cells
such as sputum-derived macrophages [29]. One strong point of
our study is that we validated the quality of the RNA that was
extracted from induced sputum cells. Immediate processing of
sputum samples (within 2 hours) may have resulted in the
satisfactory results in RNA quality.
In conclusion, we demonstrated for the first time that lower
FKBP51 expression in induced sputum cells may reflect eosino-
philic inflammation and may underlie the mechanism of GC
sensitivity in eosinophilic inflammation in the steroid-naı¨ve
condition. Longitudinal studies are necessary to further clarify
the clinical significance of overexpression of FKBP51 in patients on
steroids.
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